As our CEO Jenny Ousbey headed to the in Dubai, it was an ideal moment to take stock of the MedTech shifts shaping 2026 and why this year feels like a turning point for adoption over innovation.
AI is no longer the story, implementation is
AI-enabled diagnostics, decision-support tools and remote monitoring are now widely used, with telemedicine usage now exceeding 80% in many care settings. The growth in AI-powered medical devices continues, but the focus has moved from novelty to proof: regulators are tightening expectations around validation, transparency and real-world performance, particularly SaMD and AI-driven devices.
In short, the question is no longer can this work… but does this work at scale in real life settings?
The shift from product-led to system-led adoption
The defining change in 2026 is that good technology isn’t enough. Technologies succeed when they fit the system they’re entering. With health systems under sustained pressure, adoption is driven by solutions that:
• Improve productivity and support stretched workforce
• Reduce bottlenecks in care pathways
• Show measurable, service-level impact
This has widened the gap between innovation and uptake. Strong clinical data still matters, but so does a clear explanation of how a technology fits into day-to-day delivery.
Areas seeing real momentum
Several sub-sectors continue to attract investment and clinical interest:
• Robotics and image-guided intervention
• Structural heart and cardiology technologies
• Diabetes technologies (including longer-duration CGM)
• AI-supported diagnostics and remote monitoring
• Women’s health and screening technologies
These areas combine growing demand with clearer routes to adoption, though none are immune to system constraints.
What this means for innovators
In 2026, MedTech companies increasingly need partners who can help them operate in the real world, not just tell a compelling story. That means support with:
• NHS pathways, procurement and reimbursement
• Evidence-based value propositions that resonate beyond clinicians
• Navigating regulatory approvals, local decision-making and tariff challenges
• Digital and AI governance, including real-world evidence generation
• Bringing together clinicians, patients and system leaders in credible ways
Adoption is now a system challenge, not a sales one. The companies that recognise that, and plan accordingly, will be the ones that scale.
Article originally published on LinkedIn on 6th February 2026
